Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline

INTRODUCTION: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson’s disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the po...

Full description

Saved in:
Bibliographic Details
Published in:Endokrynologia polska 2023-01, Vol.74 (4), p.380-384
Main Authors: Soyluk, Ozlem, Bingol, Zuleyha, Ciftci, Sema, Kurtulmus, Neslihan, Tanrikulu, Seher, Yarman, Sema
Format: Article
Language:English
Subjects:
Dopamine
Pituitary gland
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 384
container_issue 4
container_start_page 380
container_title Endokrynologia polska
container_volume 74
creator Soyluk, Ozlem
Bingol, Zuleyha
Ciftci, Sema
Kurtulmus, Neslihan
Tanrikulu, Seher
Yarman, Sema
description INTRODUCTION: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson’s disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the possible pulmonary side effects of CAB in prolactinoma patients. MATERIAL AND METHODS: Chest X-ray imaging and pulmonary function parameters like forced vital capacity (FVC), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO) were evaluated in 73 prolactinoma patients. The cumulative dose of CAB and the total duration of CAB use were also calculated, and all data were reviewed retrospectively. RESULTS: The median cumulative CAB dose was 192 mg, and the median duration of CAB use was 64 months. Only 13 patients (17%) among this cohort had abnormal DLCO results that could be an indirect sign of pulmonary fibrosis. These abnormal DLCO results were found not to be associated with cumulative CAB dose in these 13 patients. CONCLUSIONS: CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.
doi_str_mv 10.5603/EP.a2023.0045
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2863245528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2863245528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c279t-fe904bf6ebdca347f40fb40b7d54162925d9e13349af4229d0d20c356aefc5473</originalsourceid><addsrcrecordid>eNotkM1PwzAMxSMEEtPYkXskzh1uvroe0TQ-pEnsAIhblKYOdOqakqQg_nsCwxcf_Gy_9yPksoSlVMCvN7ulYcD4EkDIEzJjrK6LFQd1SmYgGC9KEK_nZBHjHnIppirBZuRl82n6yaTOD9Q7Ok79wQ8mfNPYtUjRObQp0m6gY_C9sakb_MHQMS_gkAcpoEnY0q8uvVNrGgxvvu8GvCBnzvQRF_99Tp5vN0_r-2L7ePewvtkWllV1KhzWIBqnsGmt4aJyAlwjoKlaKUrFaibbGkvORW2cyIlaaBlYLpVBZ6Wo-JxcHe9mex8TxqT3fgpDfqnZSnEmpGSrrCqOKht8jAGdHkN3yCl1CfqXnt7s9B89_UuP_wA0U2ME</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2863245528</pqid></control><display><type>article</type><title>Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline</title><source>Publicly Available Content Database</source><creator>Soyluk, Ozlem ; Bingol, Zuleyha ; Ciftci, Sema ; Kurtulmus, Neslihan ; Tanrikulu, Seher ; Yarman, Sema</creator><creatorcontrib>Soyluk, Ozlem ; Bingol, Zuleyha ; Ciftci, Sema ; Kurtulmus, Neslihan ; Tanrikulu, Seher ; Yarman, Sema</creatorcontrib><description>INTRODUCTION: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson’s disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the possible pulmonary side effects of CAB in prolactinoma patients. MATERIAL AND METHODS: Chest X-ray imaging and pulmonary function parameters like forced vital capacity (FVC), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO) were evaluated in 73 prolactinoma patients. The cumulative dose of CAB and the total duration of CAB use were also calculated, and all data were reviewed retrospectively. RESULTS: The median cumulative CAB dose was 192 mg, and the median duration of CAB use was 64 months. Only 13 patients (17%) among this cohort had abnormal DLCO results that could be an indirect sign of pulmonary fibrosis. These abnormal DLCO results were found not to be associated with cumulative CAB dose in these 13 patients. CONCLUSIONS: CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.</description><identifier>ISSN: 0423-104X</identifier><identifier>EISSN: 2299-8306</identifier><identifier>DOI: 10.5603/EP.a2023.0045</identifier><language>eng</language><publisher>Wydawnictwo Via Medica</publisher><subject>Dopamine ; Pituitary gland ; Tumors</subject><ispartof>Endokrynologia polska, 2023-01, Vol.74 (4), p.380-384</ispartof><rights>2023. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2863245528?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Soyluk, Ozlem</creatorcontrib><creatorcontrib>Bingol, Zuleyha</creatorcontrib><creatorcontrib>Ciftci, Sema</creatorcontrib><creatorcontrib>Kurtulmus, Neslihan</creatorcontrib><creatorcontrib>Tanrikulu, Seher</creatorcontrib><creatorcontrib>Yarman, Sema</creatorcontrib><title>Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline</title><title>Endokrynologia polska</title><description>INTRODUCTION: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson’s disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the possible pulmonary side effects of CAB in prolactinoma patients. MATERIAL AND METHODS: Chest X-ray imaging and pulmonary function parameters like forced vital capacity (FVC), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO) were evaluated in 73 prolactinoma patients. The cumulative dose of CAB and the total duration of CAB use were also calculated, and all data were reviewed retrospectively. RESULTS: The median cumulative CAB dose was 192 mg, and the median duration of CAB use was 64 months. Only 13 patients (17%) among this cohort had abnormal DLCO results that could be an indirect sign of pulmonary fibrosis. These abnormal DLCO results were found not to be associated with cumulative CAB dose in these 13 patients. CONCLUSIONS: CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.</description><subject>Dopamine</subject><subject>Pituitary gland</subject><subject>Tumors</subject><issn>0423-104X</issn><issn>2299-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNotkM1PwzAMxSMEEtPYkXskzh1uvroe0TQ-pEnsAIhblKYOdOqakqQg_nsCwxcf_Gy_9yPksoSlVMCvN7ulYcD4EkDIEzJjrK6LFQd1SmYgGC9KEK_nZBHjHnIppirBZuRl82n6yaTOD9Q7Ok79wQ8mfNPYtUjRObQp0m6gY_C9sakb_MHQMS_gkAcpoEnY0q8uvVNrGgxvvu8GvCBnzvQRF_99Tp5vN0_r-2L7ePewvtkWllV1KhzWIBqnsGmt4aJyAlwjoKlaKUrFaibbGkvORW2cyIlaaBlYLpVBZ6Wo-JxcHe9mex8TxqT3fgpDfqnZSnEmpGSrrCqOKht8jAGdHkN3yCl1CfqXnt7s9B89_UuP_wA0U2ME</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Soyluk, Ozlem</creator><creator>Bingol, Zuleyha</creator><creator>Ciftci, Sema</creator><creator>Kurtulmus, Neslihan</creator><creator>Tanrikulu, Seher</creator><creator>Yarman, Sema</creator><general>Wydawnictwo Via Medica</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20230101</creationdate><title>Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline</title><author>Soyluk, Ozlem ; Bingol, Zuleyha ; Ciftci, Sema ; Kurtulmus, Neslihan ; Tanrikulu, Seher ; Yarman, Sema</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c279t-fe904bf6ebdca347f40fb40b7d54162925d9e13349af4229d0d20c356aefc5473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Dopamine</topic><topic>Pituitary gland</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soyluk, Ozlem</creatorcontrib><creatorcontrib>Bingol, Zuleyha</creatorcontrib><creatorcontrib>Ciftci, Sema</creatorcontrib><creatorcontrib>Kurtulmus, Neslihan</creatorcontrib><creatorcontrib>Tanrikulu, Seher</creatorcontrib><creatorcontrib>Yarman, Sema</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Endokrynologia polska</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soyluk, Ozlem</au><au>Bingol, Zuleyha</au><au>Ciftci, Sema</au><au>Kurtulmus, Neslihan</au><au>Tanrikulu, Seher</au><au>Yarman, Sema</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline</atitle><jtitle>Endokrynologia polska</jtitle><date>2023-01-01</date><risdate>2023</risdate><volume>74</volume><issue>4</issue><spage>380</spage><epage>384</epage><pages>380-384</pages><issn>0423-104X</issn><eissn>2299-8306</eissn><abstract>INTRODUCTION: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson’s disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the possible pulmonary side effects of CAB in prolactinoma patients. MATERIAL AND METHODS: Chest X-ray imaging and pulmonary function parameters like forced vital capacity (FVC), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO) were evaluated in 73 prolactinoma patients. The cumulative dose of CAB and the total duration of CAB use were also calculated, and all data were reviewed retrospectively. RESULTS: The median cumulative CAB dose was 192 mg, and the median duration of CAB use was 64 months. Only 13 patients (17%) among this cohort had abnormal DLCO results that could be an indirect sign of pulmonary fibrosis. These abnormal DLCO results were found not to be associated with cumulative CAB dose in these 13 patients. CONCLUSIONS: CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.</abstract><pub>Wydawnictwo Via Medica</pub><doi>10.5603/EP.a2023.0045</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0423-104X
ispartof Endokrynologia polska, 2023-01, Vol.74 (4), p.380-384
issn 0423-104X
2299-8306
language eng
recordid cdi_proquest_journals_2863245528
source Publicly Available Content Database
subjects Dopamine
Pituitary gland
Tumors
title Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A19%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20pulmonary%20side%20effects%20in%20prolactinoma%20patients%20treated%20with%20cabergoline&rft.jtitle=Endokrynologia%20polska&rft.au=Soyluk,%20Ozlem&rft.date=2023-01-01&rft.volume=74&rft.issue=4&rft.spage=380&rft.epage=384&rft.pages=380-384&rft.issn=0423-104X&rft.eissn=2299-8306&rft_id=info:doi/10.5603/EP.a2023.0045&rft_dat=%3Cproquest_cross%3E2863245528%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c279t-fe904bf6ebdca347f40fb40b7d54162925d9e13349af4229d0d20c356aefc5473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2863245528&rft_id=info:pmid/&rfr_iscdi=true